Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04204096
Other study ID # IVI T004
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 4, 2020
Est. completion date January 29, 2021

Study information

Verified date August 2021
Source International Vaccine Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative of SK bioscience Vi-DT in participant (6 months - 45 years) including safety population. The study objectives are as follows: - Primary objective. Demonstrate the immune equivalence as measured by anti-Vi IgG Geometric Mean Titer (GMT) of multi dose formulation against single dose formulation of Vi-DT (18-45 year age stratum), at 4 weeks after a single dose. - Secondary objective 1. Demonstrate the immune equivalence as measured by seroconversion rates of anti-Vi IgG antibody titres of multi dose formulation against single dose formulation of Vi-DT vaccine (18-45 year age stratum) at 4 weeks after a single dose. - Secondary objective 2. Describe safety profile in all age strata combined (age 6 months - 45 years old) and in each age stratum, at 4 weeks after a single dose of SD/MD formulation/control (Meningococcal Conjugate Vaccine). There are total 5 scheduled visits as follows: - Visit 1(D-7 to 0): Screening - Visit 2(D0): Enrollment, vaccination, safety follow-up and blood collection for immunogenicity assessment (only for subjects 18 years old and above) - Visit 3(D7): Safety follow-up - Visit 4(D28): Safety follow-up and blood collection for immunogenicity assessment (only for subjects 18 years old and above) - V5(D168): Safety follow-up


Description:

The vaccines will be administered to 1,500 healthy participants of 6 months to 45 years of age and followed up for 24 weeks after the injection for safety. Adult participants (N=500) will be followed up for immunogenicity at 4 weeks and all participants till 24 weeks for safety post single dose of either MD & SD formulations. 300 healthy participants will be given control vaccine (locally available licensed Meningococcal conjugate vaccine) to check the background safety events. The primary objective is to demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT titer at 4 weeks after a single dose of MD/SD formulation in adults. The secondary objective is to demonstrate the equivalence of immunogenicity in terms of seroconversion rates as measured by anti-Vi IgG ELISA antibody titers, at 4 weeks after a single dose of MD/SD formulation in adults. A descriptive evaluation of safety at 4 and 24 weeks post single dose of (SD/MD/Meningococcal vaccine), will be performed. The Vi-DT vaccine from both MD & SD formulations will be administered as a single dose of 25 µg/0.5 mL. Eligible participants enrolled into the study will be randomized into one of the three study groups within each age stratum of 6 months to less than 2 years, 2 to less than 18 years, and 18 to 45 years. Participants will be observed at the study site for 30 minutes after vaccination for safety assessment. Solicited adverse events will be recorded on a diary card during 7 days after vaccination. Unsolicited adverse events will be recorded during the 4 weeks after vaccination. Serious adverse events will be recorded during the entire study period. With the exception of designated study site personnel responsible for vaccine administration, site investigators, study nurse, and those assessing clinical outcomes, and data analysts will be blinded to vaccine allocation until data base lock for the final analysis. Blood samples will be collected at baseline prior to vaccination and at 4 weeks post vaccination from adults (18-45 years) for immunogenicity assessment


Recruitment information / eligibility

Status Completed
Enrollment 1800
Est. completion date January 29, 2021
Est. primary completion date September 11, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 45 Years
Eligibility Inclusion Criteria: 1. Healthy participants 6 months to 45 years of age at enrollment 2. Participants/Parent(s)/LAR who have voluntarily given informed consent/assent 3. Participants/Parent(s)/LAR willing to follow the study procedures of the study and available for the entire duration of the study Exclusion Criteria: 1. Child with a congenital abnormality 2. Participant who has already received meningococcal conjugate vaccine 3. Participants concomitantly enrolled or scheduled to be enrolled in another trial 4. Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders) 5. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs 6. Receipt of blood or blood-derived products in the past 3 months 7. Participant with a previously ascertained or suspected disease caused by S. Typhi (confirmed either clinically, serologically or microbiologically) 8. Participant who has had household contact with and/or intimate exposure to an individual with laboratory-confirmed S. Typhi 9. Individual who has previously received a typhoid vaccine 10. Participant who has received other vaccines from 1 month prior to test vaccination or planned to receive any vaccine within 1 month (except a measles containing vaccine as per government vaccination campaign) 11. Known history or allergy to vaccines or other medications 12. History of uncontrolled coagulopathy or blood disorders 13. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives 14. Any female participant who is lactating, pregnant* or planning for pregnancy during the course of study period 15. Participants/Parent(s)/LAR planning to move from the study area before the end of study period 16. As per Investigator's medical judgement individual could be excluded from the study in spite of meeting all inclusion/exclusion criteria mentioned above

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Vi-DT (Multi-dose formulation)
Manufacturer: SK bioscience Co., Ltd. Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE) Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years Storage Conditions: +2 to +8°C
Vi-DT (Single dose formulation)
Manufacturer: SK bioscience Co., Ltd. Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative) Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years Storage Conditions: +2 to +8°C
Control Vaccine
For participant = 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject.

Locations

Country Name City State
Philippines Lingga Health Research Center Calamba Laguna
Philippines University of the Philippines Manila-National Institutes of Health Manila
Philippines Putatan Research Center Muntinlupa Metro Manila
Philippines Magcase Health Center San Pablo City Laguna

Sponsors (3)

Lead Sponsor Collaborator
International Vaccine Institute Bill and Melinda Gates Foundation, SK Bioscience Co., Ltd.

Country where clinical trial is conducted

Philippines, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety endpoints by each formulation and overall and within each age stratum Frequency of local and systemic solicited adverse events during the 7 days after each dose
Solicited local reactions at the site of injection: pain, tenderness, erythema/redness, swelling/induration and pruritus
Solicited systemic reactions (adapted to each age group): fever, lethargy, irritability, nausea/vomiting, arthralgia, diarrhea, drowsiness, loss of appetite, chills, headache, fatigue, myalgia and persistent crying
Frequency of unsolicited adverse events during 4 weeks (28 days) after vaccination
Frequency of Serious Adverse Events during the entire study period
Solicited AEs during the 7 days after vaccination/Unsolicited AEs during 4 weeks (28 days) after vaccination/SAEs during the entire study period
Primary Geometric Mean Titers (GMT) of anti-Vi IgG If the 95% confidence interval of the ratio of GMT estimate of Vi-DT(MD) over GMT of Vi-DT(SD) is located within the bounds of 0.67to 1.5, then Vi-DT (MD) is equivalent to Vi-DT (SD) in terms of GMT of anti-Vi IgG with significance level of 0.05. At 4 weeks (28 days) post vaccination of Vi-DT (MD/SD)
Secondary Seroconversion rates of anti-Vi IgG ELISA antibody titres If the 95% confidence interval of the estimate of difference of seroconversion rate between Vi-DT (MD) and Vi-DT (SD) at 4 weeks (Day 28) is located within the bounds -10% to 10%, then Vi-DT (MD) is equivalent to Vi-DT (SD) in terms of sero-conversion rate, which is defined as 4 fold increase of anti Vi IgG from baseline with significance level of 0.05. At 4 weeks (28 days) from baseline (Day 0; before vaccination of Vi-DT (MD/SD)
See also
  Status Clinical Trial Phase
Completed NCT03312699 - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Phase 1
Completed NCT01405521 - Understanding Typhoid Disease After Vaccination Phase 2
Completed NCT00131833 - Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Phase 4
Completed NCT00125047 - Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Phase 4
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Active, not recruiting NCT03933098 - Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Phase 3
Completed NCT00679172 - Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults Phase 2
Completed NCT00125008 - Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Phase 4
Recruiting NCT04878549 - Transcriptomic Responses for the Identification of Pathogens
Completed NCT02645032 - Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Phase 1
Recruiting NCT05475379 - Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Phase 1/Phase 2
Active, not recruiting NCT03299426 - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Phase 3
Completed NCT01019083 - Studies of Immune Responses to Orally Administered Vaccines in Developing Country Phase 1/Phase 2
Completed NCT03614533 - Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Phase 2
Completed NCT00131820 - Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Phase 4
Completed NCT03527355 - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Phase 2